CSI Market
Sign In | Register

Indivior Pharmaceuticals Inc (INDV) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access INDV quarterly Cash Flow →
The data below summarizes Indivior Pharmaceuticals Inc's cash flow activity from to Dec 31 2025, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023)
Operating Activities
Income210.00
Depreciation & amortization10.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges19.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-18.00
R & D, Environmental and Other Expense0.00
Adjustments For Decrease IncreaseIn Other Assets0.00
Share-based Compensation26.00
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt-1.00
Adjustments For Sharebased Payments-
Adjustment For Settlement Of Tax On Employee Awards-
Adjustments For Decrease Increase In Inventories-
Adjustments For Increase Decrease In Trade And Other Payables-
Adjustments For Increase Decrease In Other Liabilities-
Income Taxes Refund Classified As Operating Activities-
Income Taxes Paid Classified As Operating Activities-
Equity Securities Fv Ni Unrealized Gain Loss-
Research And Development Asset Acquired Other Than Through Business Combination Written Off-
Increase Decrease In Estimated Litigation Liability10.00
Income taxes-46.00
Purchase Of Intangible Assets Classified As Investing Activities0.00
Increase (Decrease) in Accounts Receivable-3.00
Adjustments For Decrease IncreaseIn Trade Account Receivable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital-49.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-368.00
Discontinued operations0.00
Net Cash flow from Operating Activities-27.00
Investing Activities
Capital Expenditures1.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Held-to-maturity Securities19.00
Payments to Acquire Held-to-maturity Securities20.00
Real Estate Investments0.00
Proceeds From Sale Of Equity Securities Fv Ni1.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Purchase Of Financial Instruments Classified As Investing Activities0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net1.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-66.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments17.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock11.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net5.00
Other net-4.00
Increase Decrease In Cash And Cash Equivalents-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-30.00
Effect of exchange rate on cash flow-1.00
Discontinued operations0.00
Free Cash Flow-26.00
Total Cash Flow-124.00
4 historic quarters locked

Sign in to unlock the full Indivior Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Indivior Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: indv-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-012237

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License